SCHEMBL4409292

SCHEMBL4409292

Cc1cc(C#N)n(C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2521993 0.77
SCHEMBL16629527 0.76
SCHEMBL10953037 0.76
SCHEMBL15401757 0.76
SCHEMBL19805376 0.74 HDAC8 (0.31)
SCHEMBL10933572 0.72 KDM4E (0.45)
SCHEMBL24013539 0.72 KDM4E (0.34)
SCHEMBL21720948 0.72 GAA (0.40)
SCHEMBL352659 0.72 KDM4E (0.46)
SCHEMBL18436350 0.72 AR (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113278027-B Preparation method of antitumor drug Laolatinib 浙江合聚生物医药有限公司 2022-05-31 CN claimed
CN-113278027-A Preparation method of antitumor drug Laolatinib 浙江合聚生物医药有限公司 2021-08-20 CN claimed
CN-109081810-A The synthetic method of 1- methyl-3-((methylamino) methyl)-1H- pyrazoles-5- nitrile 沈阳药科大学 2018-12-25 CN claimed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
WO-2022259210-A1 NOVEL PROCESS FOR PREPARATION OF 1-METHYL-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-5-OL INCOR RENOVIS PHARMA PRIVATE LIMITED (IN) 2022-12-15 WO disclosed
US-11517561-B2 Macrocycle and composition comprising thereof SHENZHEN TARGETRX, INC. (CN) 2022-12-06 US disclosed
CN-113278027-B Preparation method of antitumor drug Laolatinib 浙江合聚生物医药有限公司 2022-05-31 CN disclosed
CN-113278027-B Preparation method of antitumor drug Laolatinib 浙江合聚生物医药有限公司 2022-05-31 CN disclosed
US-20220144854-A1 MACROCYCLIC COMPOUNDS ZENO MANAGEMENT, INC. 2022-05-12 US disclosed
US-20220144854-A1 MACROCYCLIC COMPOUNDS ZENO MANAGEMENT, INC. 2022-05-12 US disclosed
CN-113950481-A Macrocyclic compounds 芝诺管理公司 2022-01-18 CN disclosed
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 EP disclosed
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS INC. 2006-07-20 US disclosed
US-7053107-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-05-30 US disclosed
WO-2006043145-A1 INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2006-04-27 WO disclosed
CN-1747950-A 2- (1H-indazol-6-ylamino) -benzamide compounds as protein kinase inhibitors for the treatment of ocular diseases PFIZER (US) 2006-03-15 CN disclosed
EP-1585743-A1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER INC. (US) 2005-10-19 EP disclosed
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-09-30 US disclosed
WO-2004056806-A1 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES PFIZER INC. (US) 2004-07-08 WO disclosed
EP-0095289-B1 IMIDAZO(1,2-C)PYRAZOLO(3,4-E)PYRIMIDINES AND THEIR PRODUCTION WARNER-LAMBERT COMPANY (US) 1986-12-30 EP disclosed